# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0151 |
| Population Package | PP-0151 |
| Title | CTNNA1 Germline Variants |
| Version | 1.0.0 |
| Status | PASS |

---

# 1. Content QA

| Criterion | Result |
|---|---|
| Single gene-level educational question | PASS |
| CTNNA1 clearly defined | PASS |
| Germline concept included | PASS |
| Pathogenic/uncertain distinction included | PASS |
| HDGC testing role included | PASS |
| CDH1-negative pathway included | PASS |
| Gastric-cancer evidence included | PASS |
| Penetrance uncertainty included | PASS |
| Breast-cancer uncertainty included | PASS |
| Testing-availability context included | PASS |
| Family implications included | PASS |
| Evidence limitations explicitly preserved | PASS |
| No unsupported CTNNA1 management algorithm | PASS |

---

# 2. Clinical QA

| Criterion | Result |
|---|---|
| NCI HDGC PDQ prioritized | PASS |
| NCI Genetics of Gastric Cancer used | PASS |
| CTNNA1 correctly described as second HDGC-associated gene | PASS |
| CDH1/CTNNA1 evidence asymmetry preserved | PASS |
| CTNNA1 testing after CDH1-negative evaluation represented | PASS |
| Gastric-cancer risk evidence appropriately qualified | PASS |
| 57% estimate not presented as universal individual risk | PASS |
| Breast-cancer uncertainty preserved | PASS |
| Penetrance uncertainty preserved | PASS |
| Clinical-testing availability appropriately qualified | PASS |
| HDGC-like negative-testing boundary preserved | PASS |
| No CDH1 management extrapolation | PASS |
| No individual risk calculation | PASS |

---

# 3. Educational QA

| Criterion | Result |
|---|---|
| Plain-language framing | PASS |
| Evidence uncertainty visible to reader | PASS |
| No false equivalence with CDH1 | PASS |
| No deterministic language | PASS |
| Key misconceptions addressed | PASS |
| Patient-important implications emphasized | PASS |
| Technical laboratory detail excluded | PASS |

---

# 4. Governance QA

| Criterion | Result |
|---|---|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA Report completed | PASS |
| Gold Specification v1.0 followed | PASS |
| Approved Decision Batch implemented | PASS |
| Scope not reopened after approval | PASS |
| Evidence traceability documented | PASS |
| Knowledge Graph documented | PASS |
| Boundary/overlap declared | PASS |
| Versioning complete | PASS |

---

# 5. Boundary / Overlap QA

## PP-0149 — HDGC

PP-0149 owns:

- HDGC syndrome;
- clinical criteria;
- gastric/breast risk framework;
- clinical management.

PP-0151 owns:

- CTNNA1 gene;
- CTNNA1 pathogenic variants;
- evidence limitations;
- CTNNA1-specific testing role.

**Result: PASS**

## PP-0150 — CDH1 Germline Pathogenic Variants

PP-0150 owns the CDH1 gene/variant branch.

PP-0151 owns the CTNNA1 branch.

The packages are parallel rather than duplicative.

**Result: PASS**

## PP-0015 — Hereditary Gastric Cancer

PP-0015 owns the broad hereditary gastric-cancer landscape.

**Result: PASS**

## PP-0016 — Genetic Testing

PP-0016 owns the general testing framework.

PP-0151 only covers CTNNA1-specific testing context.

**Result: PASS**

## Variant Interpretation

Detailed variant classification remains delegated.

**Result: PASS**

## PP-0110 / PP-0113 / PP-0114

These remain the somatic/tumor molecular branch.

PP-0151 is explicitly germline.

**Result: PASS**

---

# 6. Clinical Safety QA

| Safety Item | Result |
|---|---|
| No personal diagnosis | PASS |
| No individual CTNNA1 risk calculation | PASS |
| No individualized surveillance recommendation | PASS |
| No individualized surgery recommendation | PASS |
| No CDH1-to-CTNNA1 management extrapolation | PASS |
| Breast-cancer uncertainty preserved | PASS |
| VUS not treated as pathogenic | PASS |
| Negative testing not treated as absolute reassurance | PASS |
| Limited evidence clearly disclosed | PASS |
| Specialist assessment boundary preserved | PASS |

---

# 7. Evidence Traceability QA

Primary:

- NCI Hereditary Diffuse Gastric Cancer (PDQ®)

Supporting:

- NCI Genetics of Gastric Cancer (PDQ®)
- NCI Cancer Genetics Risk Assessment and Counseling (PDQ®)
- ACS Stomach Cancer
- relevant project guideline materials

The strongest CTNNA1 claims are directly grounded in NCI sources.

The package deliberately preserves evidence gaps rather than filling them with assumptions from CDH1.

---

# 8. Scope Integrity QA

### Correctly Included

- CTNNA1
- alpha-catenin
- germline pathogenic variants
- role in HDGC testing
- CDH1-negative testing pathway
- gastric-cancer evidence
- penetrance uncertainty
- breast-cancer uncertainty
- testing availability
- family implications

### Correctly Excluded

- full HDGC management
- CDH1-specific risk claims
- CTNNA1-specific gastrectomy algorithm
- CTNNA1-specific surveillance schedule
- detailed variant interpretation
- NGS/laboratory methods
- detailed genetic counseling
- somatic CTNNA1 alterations

**Result: PASS**

---

# 9. Knowledge Graph QA

### Parent / Clinical Context

PP-0149 — Hereditary Diffuse Gastric Cancer

### Parallel Gene Branch

PP-0150 — CDH1 Germline Pathogenic Variants

PP-0151 — CTNNA1 Germline Variants

### Broader Framework

PP-0015 — Hereditary Gastric Cancer

PP-0016 — Genetic Testing

### Separate Somatic Branch

PP-0110 — Somatic Genetic Testing

PP-0113 — Molecular Tumor Profiling

PP-0114 — Genomic Biomarkers in Gastric Cancer

**Result: PASS**

---

# 10. Gold Artifact QA

| Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

---

# 11. Final QA Decision

# PASS

PP-0151 satisfies the locked Gold Population Package requirements.

The package maintains the critical evidence asymmetry:

**CDH1 = established / deeper evidence**

versus

**CTNNA1 = clinically relevant / substantially more uncertain evidence**

and does not manufacture a CTNNA1-specific management pathway unsupported by the Source Materials.

---

# Final Status

**APPROVED — GOLD / QA PASS**
